Skip to main content

Advertisement

SpringerLink
Log in

Frontotemporal Lobar Degeneration: Mechanisms and Therapeutic Strategies

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

Frontotemporal lobar degeneration (FTLD) is characterized by progressive deterioration of frontal and anterior temporal lobes of the brain and often exhibits frontotemporal dementia (FTD) on clinic, in <65-year-old patients at the time of diagnosis. Interdisciplinary approaches combining genetics, molecular and cell biology, and laboratory animal science have revealed some of its potential molecular mechanisms. Although there is still no effective treatment to delay, prevent, and reverse the progression of FTD, emergence of agents targeting molecular mechanisms has been beginning to promote potential pharmaceutical development. Our review summarizes the latest new findings of FTLD and challenges in FTLD therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Callister JB, Pickering-Brown SM (2014) Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS. Exp Neurol 11753:7, 4C

    Google Scholar 

  2. Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A et al (2013) The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimer’s Dement 9(2):189–198

    Article  Google Scholar 

  3. Seltman RE, Matthews BR (2012) Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drugs 26(10):841–870

    Article  CAS  PubMed  Google Scholar 

  4. Sieben A, Van Langenhove T, Engelborghs S, Martin JJ, Boon P, Cras P, De Deyn PP, Santens P, Van Broeckhoven C, Cruts M (2012) The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol 124:353–372

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Piguet O, Hornberger M, Mioshi E, Hodges JR (2011) Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol 10(2):162–172

    Article  PubMed  Google Scholar 

  6. Rosen HJ, Gorno-Tempini ML, Goldman WP, Perry RJ, Schuff N, Weiner M, Feiwell R, Kramer JH, Miller BL (2002) Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 58(2):198–208

    Article  CAS  PubMed  Google Scholar 

  7. Kanda T, Ishii K, Uemura T, Miyamoto N, Yoshikawa T, Kono AK, Mori E (2008) Comparison of grey matter and metabolic reductions in frontotemporal dementia using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging 35(12):2227–2234

    Article  PubMed  Google Scholar 

  8. Varma AR, Adams W, Lloyd JJ, Carson KJ, Snowden JS, Testa HJ, Jackson A, Neary D (2002) Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer’s disease, frontotemporal dementia and vascular dementia. Acta Neurol Scand 105(4):261–269

    Article  CAS  PubMed  Google Scholar 

  9. Rascovsky K, Hodges JR, Kipps CM, Johnson JK, Seeley WW, Mendez MF, Knopman D, Kertesz A, Mesulam M, Salmon DP et al (2007) Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis Assoc Disord 21(4):S14–S18

    Article  PubMed  Google Scholar 

  10. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M et al (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51(6):1546–1554

    Article  CAS  PubMed  Google Scholar 

  11. Peelle JE, Troiani V, Gee J, Moore P, McMillan C, Vesely L, Grossman M (2008) Sentence comprehension and voxel-based morphometry in progressive nonfluent aphasia, semantic dementia, and nonaphasic frontotemporal dementia. J Neurolinguistics 21(5):418–432

    Article  PubMed  PubMed Central  Google Scholar 

  12. Gorno-Tempini ML, Dronkers NF, Rankin KP, Ogar JM, Phengrasamy L, Rosen HJ, Johnson JK, Weiner MW, Miller BL (2004) Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 55(3):335–346

    Article  PubMed  PubMed Central  Google Scholar 

  13. Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW (2011) Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol 7(5):263–272

    Article  CAS  PubMed  Google Scholar 

  14. Josephs KA, Tang-Wai DF, Edland SD, Knopman DS, Dickson DW, Parisi JE, Petersen RC, Jack CR Jr, Boeve BF (2004) Correlation between antemortem magnetic resonance imaging findings and pathologically confirmed corticobasal degeneration. Arch Neurol 61(12):1881–1884

    Article  PubMed  Google Scholar 

  15. Josephs KA, Whitwell JL, Dickson DW, Boeve BF, Knopman DS, Petersen RC, Parisi JE, Jack CR Jr (2008) Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging 29(2):280–289

    Article  PubMed  Google Scholar 

  16. Rohrer JD, Nicholas JM, Cash DM, van Swieten J, Dopper E, Jiskoot L, van Minkelen R, Rombouts SA, Cardoso MJ, Clegg S et al (2015) Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol 14(3):253–262

    Article  PubMed  Google Scholar 

  17. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A et al (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393(6686):702–705

    Article  CAS  PubMed  Google Scholar 

  18. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S et al (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442(7105):916–919

    Article  CAS  PubMed  Google Scholar 

  19. Marc Cruts IG, Van Langenhove T, van der Zee J, Van Broeckhoven C (2013) Current insights into the C9orf72 repeat expansion diseases of the FTLDALS spectrum. Trends Neurosci 36(8):450–459

    Article  PubMed  CAS  Google Scholar 

  20. Fontana F, Siva K, Denti MA (2015) A network of RNA and protein interactions in fronto temporal dementia. Front Mol Neurosci 8:9

    Article  PubMed  PubMed Central  Google Scholar 

  21. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, Yang Y, Fecto F, Shi Y, Zhai H et al (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477(7363):211–215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JB, Dobson-Stone C, Brooks WS, Schofield PR, Halliday GM et al (2014) Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol 13(7):686–699

    Article  PubMed  PubMed Central  Google Scholar 

  23. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, White CL 3rd, Schneider JA, Grinberg LT, Halliday G et al (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114(1):5–22

    Article  PubMed  PubMed Central  Google Scholar 

  24. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE et al (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119(1):1–4

    Article  PubMed  Google Scholar 

  25. Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, Perry RH, Trojanowski JQ, Mann DM, Lee VM (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122(1):111–113

    Article  PubMed  PubMed Central  Google Scholar 

  26. Rohrer JD, Lashley T, Schott JM, Warren JE, Mead S, Isaacs AM, Beck J, Hardy J, de Silva R, Warrington E et al (2011) Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain J Neurol 134(Pt 9):2565–2581

    Article  Google Scholar 

  27. Whitwell JL, Josephs KA (2011) Neuroimaging in frontotemporal lobar degeneration–predicting molecular pathology. Nat Rev Neurol 8(3):131–142

    Article  CAS  Google Scholar 

  28. McMillan CT, Irwin DJ, Avants BB, Powers J, Cook PA, Toledo JB, McCarty Wood E, Van Deerlin VM, Lee VM, Trojanowski JQ et al (2013) White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 84(9):949–955

    Article  PubMed  PubMed Central  Google Scholar 

  29. Diaper DC, Adachi Y, Sutcliffe B, Humphrey DM, Elliott CJ, Stepto A, Ludlow ZN, Vanden Broeck L, Callaerts P, Dermaut B et al (2013) Loss and gain of Drosophila TDP-43 impair synaptic efficacy and motor control leading to age-related neurodegeneration by loss-of-function phenotypes. Hum Mol Genet 22(8):1539–1557

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kabashi E, Lin L, Tradewell ML, Dion PA, Bercier V, Bourgouin P, Rochefort D, Bel Hadj S, Durham HD, Vande Velde C et al (2010) Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet 19(4):671–683

    Article  CAS  PubMed  Google Scholar 

  31. Ash PE, Zhang YJ, Roberts CM, Saldi T, Hutter H, Buratti E, Petrucelli L, Link CD (2010) Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum Mol Genet 19(16):3206–3218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Xu YF, Zhang YJ, Lin WL, Cao X, Stetler C, Dickson DW, Lewis J, Petrucelli L (2011) Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Mol Neurodegener 6:73

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Shan X, Chiang PM, Price DL, Wong PC (2010) Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc Natl Acad Sci U S A 107(37):16325–16330

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Tsai KJ, Yang CH, Fang YH, Cho KH, Chien WL, Wang WT, Wu TW, Lin CP et al (2010) Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. J Exp Med 207(8):1661–1673

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Janssens J, Wils H, Kleinberger G, Joris G, Cuijt I, Ceuterick-de Groote C, Van Broeckhoven C, Kumar-Singh S (2013) Overexpression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. Mol Neurobiol 48(1):22–35

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Arnold ES, Ling SC, Huelga SC, Lagier-Tourenne C, Polymenidou M, Ditsworth D, Kordasiewicz HB, McAlonis-Downes M et al (2013) ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S A 110(8):E736–E745

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Swarup V, Phaneuf D, Bareil C, Robertson J, Rouleau GA, Kriz J, Julien JP (2011) Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain 134(Pt 9):2610–2626

    Article  PubMed  Google Scholar 

  38. Igaz LM, Kwong LK, Lee EB, Chen-Plotkin A, Swanson E, Unger T, Malunda J, Xu Y et al (2011) Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest 121(2):726–738

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Caccamo A, Majumder S, Oddo S (2012) Cognitive decline typical of frontotemporal lobar degeneration in transgenic mice expressing the 25-kDa C-terminal fragment of TDP-43. Am J Pathol 180(1):293–302

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Probst A, Gotz J, Wiederhold KH, Tolnay M, Mistl C, Jaton AL, Hong M, Ishihara T et al (2000) Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol 99(5):469–481

    Article  CAS  PubMed  Google Scholar 

  41. Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M et al (2005) Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 25(46):10637–10647

    Article  CAS  PubMed  Google Scholar 

  42. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M et al (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25(4):402–405

    Article  CAS  PubMed  Google Scholar 

  43. Nilsen LH, Rae C, Ittner LM, Gotz J, Sonnewald U (2013) Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation. J Cereb Blood Flow Metab 33(5):684–691

    Article  PubMed  CAS  Google Scholar 

  44. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T et al (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53(3):337–351

    Article  CAS  PubMed  Google Scholar 

  45. van Eersel J, Stevens CH, Przybyla M, Gladbach A, Stefanoska K, Chan CK, Ong WY, Hodges JR et al (2015) Early-onset axonal pathology in a novel P301S-Tau transgenic mouse model of frontotemporal lobar degeneration. Neuropathol Appl Neurobiol. doi:10.1111/nan.12233

    PubMed  Google Scholar 

  46. Ittner LM, Fath T, Ke YD, Bi M, van Eersel J, Li KM, Gunning P, Gotz J (2008) Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci U S A 105(41):15997–16002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Lambourne SL, Humby T, Isles AR, Emson PC, Spillantini MG, Wilkinson LS (2007) Impairments in impulse control in mice transgenic for the human FTDP-17 tauV337M mutation are exacerbated by age. Hum Mol Genet 16(14):1708–1719

    Article  CAS  PubMed  Google Scholar 

  48. Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, Petrova O, Schonig K et al (2008) The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci 28(3):737–748

    Article  CAS  PubMed  Google Scholar 

  49. Umeda T, Yamashita T, Kimura T, Ohnishi K, Takuma H, Ozeki T, Takashima A, Tomiyama T et al (2013) Neurodegenerative disorder FTDP-17-related tau intron 10 +16C –> T mutation increases tau exon 10 splicing and causes tauopathy in transgenic mice. Am J Pathol 183(1):211–225

    Article  CAS  PubMed  Google Scholar 

  50. Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, Yu X, Wuertzer CA et al (2010) Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol 177(1):311–324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Maria Grazia Spillantini MG (2013) Tau pathology and neurodegeneration. Lancet Neurol 12:609–622

    Article  PubMed  CAS  Google Scholar 

  52. Melis V, Zabke C, Stamer K, Magbagbeolu M, Schwab K, Marschall P, Veh RW, Bachmann S et al (2015) Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer's disease and frontotemporal lobar degeneration. Cell Mol Life Sci 72(11):2199–2222

    Article  CAS  PubMed  Google Scholar 

  53. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA et al (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68(6):1067–1081

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Lim S, Haque MM, Kim D, Kim DJ, Kim YK (2014) Cell-based models to investigate Tau aggregation. Comput Struct Biotechnol J 12(20–21):7–13

    Article  PubMed  PubMed Central  Google Scholar 

  55. Frost B, Jacks RL, Diamond MI (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284(19):12845–12852

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Ahmed Z, Cooper J, Murray TK, Garn K, McNaughton E, Clarke H, Parhizkar S, Ward MA et al (2014) A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol 127(5):667–683

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Karch CM, Jeng AT, Goate AM (2012) Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. J Biol Chem 287(51):42751–42762

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Kuchibhotla KV, Wegmann S, Kopeikina KJ, Hawkes J, Rudinskiy N, Andermann ML, Spires-Jones TL, Bacskai BJ et al (2014) Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. PNAS 111(1):510–514

    Article  CAS  PubMed  Google Scholar 

  59. SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M et al (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309(5733):476–481

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Blair LJ, Nordhues BA, Hill SE, Scaglione KM, O'Leary JC 3rd, Fontaine SN, Breydo L, Zhang B et al (2013) Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest 123(10):4158–4169

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, Estes DM, Barrett AD et al (2014) Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 34(12):4260–4272

    Article  PubMed  CAS  Google Scholar 

  62. Moussavi Nik SH, Newman M, Ganesan S, Chen M, Martins R, Verdile G, Lardelli M (2014) Hypoxia alters expression of Zebrafish Microtubule-associated protein Tau (mapta, maptb) gene transcripts. BMC Research Notes 7:767

    Article  PubMed  PubMed Central  Google Scholar 

  63. Planel E, Tatebayashi Y, Miyasaka T, Liu L, Wang L, Herman M, Yu WH, Luchsinger JA et al (2007) Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci 27(50):13635–13648

    Article  CAS  PubMed  Google Scholar 

  64. Patrick C, Crews L, Desplats P, Dumaop W, Rockenstein E, Achim CL, Everall IP, Masliah E (2011) Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with Roscovitine. Am J Pathol 178(4):1646–1661

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX (2004) O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A 101(29):10804–10809

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Hanger DP, Noble W (2011) Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int J Alzheimers Dis 2011:352805

    PubMed  PubMed Central  Google Scholar 

  67. Chow HM, Guo D, Zhou JC, Zhang GY, Li HF, Herrup K, Zhang J (2014) CDK5 activator protein p25 preferentially binds and activates GSK3beta. Proc Natl Acad Sci U S A 111(45):E4887–E4895

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Zhao L, Chu CB, Li JF, Yang YT, Niu SQ, Qin W, Hao YG, Dong Q et al (2013) Glycogen synthase kinase-3 reduces acetylcholine level in striatum via disturbing cellular distribution of choline acetyltransferase in cholinergic interneurons in rats. Neuroscience 255:203–211

    Article  CAS  PubMed  Google Scholar 

  69. Hashiguchi M, Saito T, Hisanaga S, Hashiguchi T (2002) Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J Biol Chem 277(46):44525–44530

    Article  CAS  PubMed  Google Scholar 

  70. Wendy Noble VO et al (2003) Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38:555–565

    Article  PubMed  Google Scholar 

  71. Li T, Hawkes C, Qureshi HY, Kar S, Paudel HK (2006) Cyclindependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. Biochemistry 45(10):3134–3145

    Article  CAS  PubMed  Google Scholar 

  72. Gotz J, Gladbach A, Pennanen L, van Eersel J, Schild A, David D, Ittner LM (2010) Animal models reveal role for tau phosphorylation in human disease. Biochim Biophys Acta 1802(10):860–871

    Article  CAS  PubMed  Google Scholar 

  73. Luo DJ, Feng Q, Wang ZH, Sun DS, Wang Q, Wang JZ, Liu GP (2014) Knockdown of phosphotyrosyl phosphatase activator induces apoptosis via mitochondrial pathway and the attenuation by simultaneous tau hyperphosphorylation. J Neurochem 130(6):816–825

    Article  CAS  PubMed  Google Scholar 

  74. Castro-Alvarez JF, Uribe-Arias SA, Mejia-Raigosa D, Cardona-Gomez GP (2014) Cyclin-dependent kinase 5, a node protein in diminished tauopathy: a systems biology approach. Front Aging Neurosci 6:232

    PubMed  PubMed Central  Google Scholar 

  75. Kimura T, Ishiguro K, Hisanaga S (2014) Physiological and pathological phosphorylation of tau by Cdk5. Front Mol Neurosci 7:65

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  76. Bennion Callister J, Pickering-Brown SM (2014) Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS. Exp Neurol 262 Pt B:84–90

    Article  PubMed  CAS  Google Scholar 

  77. Medina DX, Orr ME, Oddo S (2014) Accumulation of C-terminal fragments of transactive response DNA-binding protein 43 leads to synaptic loss and cognitive deficits in human TDP-43 transgenic mice. Neurobiol Aging 35(1):79–87

    Article  CAS  PubMed  Google Scholar 

  78. Iguchi Y, Katsuno M, Niwa J, Takagi S, Ishigaki S, Ikenaka K, Kawai K, Watanabe H et al (2013) Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain 136(Pt 5):1371–1382

    Article  PubMed  Google Scholar 

  79. Ke YD, van Hummel A, Stevens CH, Gladbach A, Ippati S, Bi M, Lee WS, Kruger S et al (2015) Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Acta Neuropathol 130(5):661–678

    Article  CAS  PubMed  Google Scholar 

  80. Fuentealba RA, Udan M, Bell S, Wegorzewska I, Shao J, Diamond MI, Weihl CC, Baloh RH (2010) Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43. J Biol Chem 285(34):26304–26314

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Tao Zhang GB, Periz G, Wang J (2014) RNA-processing protein TDP-43 regulates FOXO-dependent protein quality control in stress response. PLoS Genet 10(10):e1004693

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Xu ZS (2012) Does a loss of TDP-43 function cause neurodegeneration? Mol Neurodegener 7:27

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, Smits V, Ceuterick-de Groote C et al (2010) TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 107(8):3858–3863

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Vanden Broeck L, Kleinberger G, Chapuis J, Gistelinck M, Amouyel P, Van Broeckhoven C, Lambert JC, Callaerts P et al (2015) Functional complementation in Drosophila to predict the pathogenicity of TARDBP variants: evidence for a loss-of-function mechanism. Neurobiol Aging 36(2):1121–1129

    Article  CAS  PubMed  Google Scholar 

  85. Ward ME, Taubes A, Chen R, Miller BL, Sephton CF, Gelfand JM, Minami S, Boscardin J et al (2014) Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD. J Exp Med 211(10):1937–1945

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Alquezar C, Esteras N, Bartolome F, Merino JJ, Alzualde A, Lopez de Munain A, Martin-Requero A (2012) Alteration in cell cycle-related proteins in lymphoblasts from carriers of the c.709-1G>A PGRN mutation associated with FTLD-TDP dementia. Neurobiol Aging 33(2):429, e427-420

    Article  PubMed  CAS  Google Scholar 

  87. Mutihac R, Alegre-Abarrategui J, Gordon D, Farrimond L, Yamasaki-Mann M, Talbot K, Wade-Martins R (2015) TARDBP pathogenic mutations increase cytoplasmic translocation of TDP-43 and cause reduction of endoplasmic reticulum Ca(2+) signaling in motor neurons. Neurobiol Dis 75:64–77

    Article  CAS  PubMed  Google Scholar 

  88. Wils H, Kleinberger G, Pereson S, Janssens J, Capell A, Van Dam D, Cuijt I, Joris G et al (2012) Cellular ageing, increased mortality and FTLD-TDP-associated neuropathology in progranulin knockout mice. J Pathol 228(1):67–76

    CAS  PubMed  Google Scholar 

  89. Guo A, Tapia L, Bamji SX, Cynader MS, Jia W (2010) Progranulin deficiency leads to enhanced cell vulnerability and TDP-43 translocation in primary neuronal cultures. Brain Res 1366:1–8

    Article  CAS  PubMed  Google Scholar 

  90. Cruts M, Gijselinck I, Van Langenhove T, van der Zee J, Van Broeckhoven C (2013) Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci 36(8):450–459

    Article  CAS  PubMed  Google Scholar 

  91. Brady OA, Meng P, Zheng Y, Mao Y, Hu F (2011) Regulation of TDP-43 aggregation by phosphorylation and p62/SQSTM1. J Neurochem 116(2):248–259

    Article  CAS  PubMed  Google Scholar 

  92. Wang IF, Tsai KJ, Shen CK (2013) Autophagy activation ameliorates neuronal pathogenesis of FTLD-U mice, a new light for treatment of TARDBP/TDP-43 proteinopathies. Autophagy 9(2):239–240

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Ritson GP, Custer SK, Freibaum BD, Guinto JB, Geffel D, Moore J, Tang W, Winton MJ et al (2010) TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci 30(22):7729–7739

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Rumpf S, Bagley JA, Thompson-Peer KL, Zhu S, Gorczyca D, Beckstead RB, Jan LY, Jan YN (2014) Drosophila valosin-containing protein is required for dendrite pruning through a regulatory role in mRNA metabolism. Proc Natl Acad Sci U S A 111(20):7331–7336

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Bieniek KF, Murray ME, Rutherford NJ, Castanedes-Casey M, DeJesus-Hernandez M, Liesinger AM, Baker MC, Boylan KB et al (2013) Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathol 125(2):289–302

    Article  CAS  PubMed  Google Scholar 

  96. King A, Al-Sarraj S, Troakes C, Smith BN, Maekawa S, Iovino M, Spillantini MG, Shaw CE (2013) Mixed tau, TDP-43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and p.Ala239Thr MAPT (tau) variant. Acta Neuropathol 125(2):303–310

    Article  CAS  PubMed  Google Scholar 

  97. Clippinger AK, D’Alton S, Lin WL, Gendron TF, Howard J, Borchelt DR, Cannon A, Carlomagno Y, Chakrabarty P, Cook C et al (2013) Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy. Acta Neuropathol 126(1):39–50

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Jinwal UK, Abisambra JF, Zhang J, Dharia S, O’Leary JC, Patel T, Braswell K, Jani T, Gestwicki JE, Dickey CA (2012) Cdc37/Hsp90 protein complex disruption triggers an autophagic clearance cascade for TDP-43 protein. J Biol Chem 287(29):24814–24820

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Liachko NF, McMillan PJ, Strovas TJ, Loomis E, Greenup L, Murrell JR, Ghetti B, Raskind MA, Montine TJ, Bird TD et al (2014) The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43. PLoS Genet 10(12):e1004803

    Article  PubMed  PubMed Central  Google Scholar 

  100. Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, Marinec PS, Gestwicki JE, Dickey CA, Yu WH, Duff KE (2012) Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 8(4):609–622

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Jiang T, Yu JT, Zhu XC, Zhang QQ, Cao L, Wang HF, Tan MS, Gao Q, Qin H, Zhang YD et al (2014) Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance. Neuropharmacology 85:121–130

    Article  CAS  PubMed  Google Scholar 

  102. Tolosa E, Litvan I, Hoglinger GU, Burn D, Lees A, Andres MV, Gomez-Carrillo B, Leon T, Del Ser T (2014) A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 29(4):470–478

    Article  CAS  PubMed  Google Scholar 

  103. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G et al (2004) CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 13(7):703–714

    Article  CAS  PubMed  Google Scholar 

  104. Kruger U, Wang Y, Kumar S, Mandelkow EM (2012) Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiol Aging 33(10):2291–2305

    Article  PubMed  CAS  Google Scholar 

  105. Caccamo A, Magri A, Medina DX, Wisely EV, Lopez-Aranda MF, Silva AJ, Oddo S (2013) mTOR regulates tau phosphorylation and degradation: implications for Alzheimer’s disease and other tauopathies. Aging Cell 12(3):370–380

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M (2014) First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model. Alzheimers Res Ther 6(4):44

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  107. Golde TE, Lewis J, McFarland NR (2013) Anti-tau antibodies: hitting the target. Neuron 80(2):254–256

    Article  CAS  PubMed  Google Scholar 

  108. Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM, Iba M, James MJ, Xie SX, Ballatore C et al (2010) Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci 30(41):13861–13866

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, Li C et al (2005) Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A 102(1):227–231

    Article  CAS  PubMed  Google Scholar 

  110. Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR et al (2014) Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 13(7):676–685

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Yamashita M, Nonaka T, Arai T, Kametani F, Buchman VL, Ninkina N, Bachurin SO, Akiyama H, Goedert M, Hasegawa M (2009) Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett 583(14):2419–2424

    Article  CAS  PubMed  Google Scholar 

  112. Wang IF, Guo BS, Liu YC, Wu CC, Yang CH, Tsai KJ, Shen CK (2012) Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc Natl Acad Sci U S A 109(37):15024–15029

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, Andres PL, Mahoney K, Allred P, Alexander K et al (2013) An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 12(5):435–442

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Cenik B, Sephton CF, Dewey CM, Xian X, Wei S, Yu K, Niu W, Coppola G, Coughlin SE, Lee SE et al (2011) Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J Biol Chem 286(18):16101–16108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Gass J, Prudencio M, Stetler C, Petrucelli L (2012) Progranulin: an emerging target for FTLD therapies. Brain Res 1462:118–128

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Capell A, Liebscher S, Fellerer K, Brouwers N, Willem M, Lammich S, Gijselinck I, Bittner T, Carlson AM, Sasse F et al (2011) Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J Neurosci 31(5):1885–1894

    Article  CAS  PubMed  Google Scholar 

  117. Hu F, Padukkavidana T, Vaegter CB, Brady OA, Zheng Y, Mackenzie IR, Feldman HH, Nykjaer A, Strittmatter SM (2010) Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 68(4):654–667

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Chen-Plotkin AS, Unger TL, Gallagher MD, Bill E, Kwong LK, Volpicelli-Daley L, Busch JI, Akle S, Grossman M, Van Deerlin V et al (2012) TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci 32(33):11213–11227

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Tsai RM, Boxer AL (2014) Treatment of frontotemporal dementia. Curr Treat Options Neurol 16(11):319

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (81471309, 81371406, 81571245, and 81501103), the Shandong Provincial Outstanding Medical Academic Professional Program, Qingdao Key Health Discipline Development Fund, Qingdao Outstanding Health Professional Development Fund, and Shandong Provincial Collaborative Innovation Center for Neurodegenerative Disorders.

Author information

Authors and Affiliations

  1. Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, China

    Ya-Qing Li, Meng-Shan Tan, Jin-Tai Yu & Lan Tan

  2. Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA

    Jin-Tai Yu

Authors
  1. Ya-Qing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meng-Shan Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jin-Tai Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lan Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jin-Tai Yu or Lan Tan.

Ethics declarations

Conflicts of Interest

The authors declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, YQ., Tan, MS., Yu, JT. et al. Frontotemporal Lobar Degeneration: Mechanisms and Therapeutic Strategies. Mol Neurobiol 53, 6091–6105 (2016). https://doi.org/10.1007/s12035-015-9507-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-015-9507-5

Keywords

Search

Navigation